AU2019415848A1 - Claudin18.2 binding moieties and uses thereof - Google Patents

Claudin18.2 binding moieties and uses thereof Download PDF

Info

Publication number
AU2019415848A1
AU2019415848A1 AU2019415848A AU2019415848A AU2019415848A1 AU 2019415848 A1 AU2019415848 A1 AU 2019415848A1 AU 2019415848 A AU2019415848 A AU 2019415848A AU 2019415848 A AU2019415848 A AU 2019415848A AU 2019415848 A1 AU2019415848 A1 AU 2019415848A1
Authority
AU
Australia
Prior art keywords
seq
amino acid
nos
acid sequences
cdr1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2019415848A
Other languages
English (en)
Other versions
AU2019415848A8 (en
Inventor
Xiaohu FAN
Zhuo FANG
Yong Liu
Jie Mao
Bo Wu
Liusong YIN
Qingshan Zhang
Dan Zhao
Tielin ZHOU
Qiuchuan ZHUANG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nanjing Jinsirui Science and Technology Biology Corp
Nanjing Legend Biotechnology Co Ltd
Original Assignee
Nanjing Legend Biotech Co Ltd
Nanjing Jinsirui Science and Technology Biology Corp
Nanjing Legend Biotechnology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanjing Legend Biotech Co Ltd, Nanjing Jinsirui Science and Technology Biology Corp, Nanjing Legend Biotechnology Co Ltd filed Critical Nanjing Legend Biotech Co Ltd
Publication of AU2019415848A1 publication Critical patent/AU2019415848A1/en
Publication of AU2019415848A8 publication Critical patent/AU2019415848A8/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2019415848A 2018-12-28 2019-12-27 Claudin18.2 binding moieties and uses thereof Pending AU2019415848A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN2018125052 2018-12-28
CNPCT/CN2018/125052 2018-12-28
CNPCT/CN2019/095827 2019-07-12
CN2019095827 2019-07-12
PCT/CN2019/129017 WO2020135674A1 (en) 2018-12-28 2019-12-27 Claudin18.2 binding moieties and uses thereof

Publications (2)

Publication Number Publication Date
AU2019415848A1 true AU2019415848A1 (en) 2021-08-19
AU2019415848A8 AU2019415848A8 (en) 2021-09-02

Family

ID=71127698

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019415848A Pending AU2019415848A1 (en) 2018-12-28 2019-12-27 Claudin18.2 binding moieties and uses thereof

Country Status (12)

Country Link
US (1) US12258418B2 (enExample)
EP (1) EP3902839A4 (enExample)
JP (2) JP2022515487A (enExample)
KR (1) KR20210110339A (enExample)
CN (1) CN113227146B (enExample)
AU (1) AU2019415848A1 (enExample)
BR (1) BR112021012608A2 (enExample)
CA (1) CA3125193A1 (enExample)
IL (1) IL284393A (enExample)
MX (1) MX2021007939A (enExample)
SG (1) SG11202106534RA (enExample)
WO (1) WO2020135674A1 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3138414A1 (en) * 2019-05-16 2020-11-19 Qilu Pharmaceutical Co., Ltd. Antibodyagainst claudin 18a2 and use thereof
PE20221459A1 (es) 2019-11-05 2022-09-21 Lanova Medicines Ltd Conjugados anticuerpo-farmaco dirigido a claudina 18.2
CN113637082A (zh) * 2020-04-27 2021-11-12 启愈生物技术(上海)有限公司 一种靶向人claudin和人PDL1蛋白的双特异抗体及其应用
US12492252B2 (en) 2020-07-01 2025-12-09 Shandong Boan Biotechnology Co., Ltd. Anti-GPC3 antibody, anti-GPC3 chimeric antigen receptor and GPC3/CD3 bispecific antibody
CN113929780A (zh) * 2020-07-13 2022-01-14 北京凯因科技股份有限公司 一种结合密蛋白的用于治疗癌症的人源化抗体
US20240270839A1 (en) * 2020-09-28 2024-08-15 Elpiscience (Suzhou) Biopharma, Ltd. Novel anti-claudin18 antibodies
JP2023548538A (ja) 2020-11-08 2023-11-17 シージェン インコーポレイテッド 併用療法
CN114560941B (zh) * 2020-11-27 2024-01-16 广东东阳光药业股份有限公司 Cldn18.2的抗体及其应用
CN114539402B (zh) * 2020-11-27 2025-06-13 南京北恒生物科技有限公司 靶向Claudin18.2的抗体及其用途
WO2022122709A1 (en) 2020-12-07 2022-06-16 Sotio Biotech A.S. Antibody-drug conjugates based on humanized cldn18.2 antibodies
PE20231561A1 (es) 2020-12-23 2023-10-03 Sotio Biotech A S Conjugados anticuerpo-farmaco especificos para tumores con claudina 18.2
CN113321730B (zh) * 2021-01-11 2023-10-10 上海莱馥医疗科技有限公司 Cldn18.2抗体及其应用
CN116940598A (zh) * 2021-02-08 2023-10-24 山东博安生物技术股份有限公司 用于治疗表达cldn18.2的实体瘤的cldn18.2/cd3双特异性抗体
CN115109154A (zh) * 2021-03-17 2022-09-27 三优生物医药(上海)有限公司 一种靶向cldn18.2的抗体或其抗原结合片段及其应用
CN117083299A (zh) * 2021-04-02 2023-11-17 原启生物科技(上海)有限责任公司 Cldn18.2抗原结合蛋白及其用途
JP7675818B2 (ja) * 2021-05-08 2025-05-13 レメゲン シーオー．，エルティーディー． 抗クローディン－１８．２抗体及びその抗体薬物複合体
KR20230132640A (ko) 2022-03-04 2023-09-15 앱티스 주식회사 티올 반응성 에디티브를 이용한 항체-약물 컨쥬게이트의 제조 수율을 높이는 방법
WO2024096564A1 (ko) 2022-11-01 2024-05-10 앱티스 주식회사 항-클라우딘18.2 항체를 포함하는 항체-약물 컨쥬게이트 및 이의 암에 대한 치료용도
TW202434307A (zh) 2023-01-18 2024-09-01 大陸商泰勵生物科技（上海）有限公司 抗體偶聯藥物及其用途
CN116284224B (zh) * 2023-05-12 2023-07-25 中国农业大学 一种结合Claudin 18.2的环肽及其应用
WO2025038602A1 (en) * 2023-08-14 2025-02-20 Ginkgo Bioworks, Inc. Immune cell stimulatory sequences
WO2025059162A1 (en) 2023-09-11 2025-03-20 Dana-Farber Cancer Institute, Inc. Car-engager containing il-2 variants to enhance the functionality of car t cells
WO2025072299A1 (en) * 2023-09-25 2025-04-03 Duke University Compositions comprising hiv envelopes to induce hiv-1 antibodies
CN120829517A (zh) * 2024-04-22 2025-10-24 鲁南新时代生物技术有限公司 抗cldn18.2/cd3双特异性抗体及用途
WO2025251228A1 (en) 2024-06-05 2025-12-11 Nuwacell Biotechnologies Co., Ltd. Cldn18.2-targeting chimeric antigen receptor and engineered cell

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1790664A1 (en) * 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
EP1997832A1 (en) * 2007-05-29 2008-12-03 Ganymed Pharmaceuticals AG Monoclonal antibodies against Claudin-18 for treatment of cancer
WO2013174404A1 (en) * 2012-05-23 2013-11-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2013174403A1 (en) 2012-05-23 2013-11-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2014127785A1 (en) 2013-02-20 2014-08-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
CN105315375B (zh) * 2014-07-17 2021-04-23 恺兴生命科技(上海)有限公司 靶向cld18a2的t淋巴细胞及其制备方法和应用
WO2016165762A1 (en) 2015-04-15 2016-10-20 Ganymed Pharmaceuticals Ag Drug conjugates comprising antibodies against claudin 18.2
WO2016180468A1 (en) * 2015-05-11 2016-11-17 Biontech Cell & Gene Therapies Gmbh Claudin-18.2-specific immunoreceptors and t cell epitopes
BR112019000327A8 (pt) * 2016-07-08 2022-10-18 Carsgen Therapeutics Co Ltd Anticorpo para anticlaudina 18a2 e uso do mesmo
IL276830B2 (en) * 2018-03-08 2025-08-01 Phanes Therapeutics Inc Anti-claudin 18.2 antibodies and uses thereof
AU2019270865B2 (en) * 2018-05-18 2023-03-30 LaNova Medicines Limited Anti-claudin 18.2 antibodies and uses thereof
EP3917564A4 (en) * 2019-02-01 2022-12-21 NovaRock Biotherapeutics, Ltd. ANTI-CLAUDINE 18 ANTIBODIES AND THEIR METHODS OF USE
US20220306765A1 (en) * 2019-08-20 2022-09-29 Suzhou Transcenta Therapeutics Co., Ltd. Novel anti-cldn18.2 antibodies

Also Published As

Publication number Publication date
CA3125193A1 (en) 2020-07-02
BR112021012608A2 (pt) 2021-09-08
MX2021007939A (es) 2021-10-22
KR20210110339A (ko) 2021-09-07
EP3902839A1 (en) 2021-11-03
US20220073643A1 (en) 2022-03-10
US12258418B2 (en) 2025-03-25
CN113227146B (zh) 2024-03-01
JP2024125370A (ja) 2024-09-18
IL284393A (en) 2021-08-31
JP2022515487A (ja) 2022-02-18
CN113227146A (zh) 2021-08-06
JP7724332B2 (ja) 2025-08-15
SG11202106534RA (en) 2021-07-29
WO2020135674A1 (en) 2020-07-02
AU2019415848A8 (en) 2021-09-02
EP3902839A4 (en) 2022-12-14

Similar Documents

Publication Publication Date Title
US12258418B2 (en) Claudin18.2 binding moieties and uses thereof
JP7196076B2 (ja) がんの処置のための抗ｔｎｆ関連アポトーシス誘発リガンド受容体２及び抗カドヘリン１７結合性二重特異的分子
CN113195542B (zh) Cd30-结合部分、嵌合抗原受体及其用途
AU2019326635B2 (en) Anti-PD-L1/anti-LAG3 bispecific antibodies and uses thereof
EP4273170A1 (en) Pharmaceutical composition comprising anti-tigit antibody and anti-pd-1-anti-vegfa bispecific antibody, and use
CA3230426A1 (en) Bispecific binding proteins that bind cd137 and a tumor associated antigen
CN116390953A (zh) 靶向人密蛋白18.2的抗体及其用途
CN119278213A (zh) 针对ctla-4的抗体及其使用方法
CN109970859B (zh) Glypican-3特异性抗体及其特异性CAR-T细胞
WO2025016459A1 (zh) 一种抗fgfr2/pd-1双特异性抗体
US20230136252A1 (en) Glypican-2-binding moieties, chimeric antigen receptors and uses thereof
EA047760B1 (ru) Группы, связывающие клаудин 18.2, и их использование
WO2025237420A1 (en) Her2 targetting antibodies, chimeric antigen receptors, and uses thereof
EP4491636A1 (en) Antibody or antigen-binding fragment thereof that targets cotinine, chimeric antigen receptor comprising same, and uses thereof
TW202400232A (zh) 多特異性分子與免疫檢查點抑制劑之組合
WO2026002239A1 (zh) 靶向cd155的抗原结合蛋白及其应用
HK40100877A (en) Pharmaceutical composition comprising anti-tigit antibody and anti-pd-1-anti-vegfa bispecific antibody, and use
JP2022174194A (ja) がんの処置のための抗ｔｎｆ関連アポトーシス誘発リガンド受容体２及び抗カドヘリン１７結合性二重特異的分子
TW202305011A (zh) 靶向ｐｄ－１和／或ｏｘ４０的特異性結合蛋白
HK40089230A (zh) 药物组合物及用途
CN118234511A (zh) 与cd137和肿瘤相关抗原结合的双特异性结合蛋白
Asgarov Development of more precise and efficient antibodies for cancer targeting: membrane associated form specific anti-mesothelin antibodies and CAR as an example

Legal Events

Date Code Title Description
TH Corrigenda

Free format text: IN VOL 35 , NO 33 , PAGE(S) 6761 UNDER THE HEADING PCT APPLICATIONS THAT HAVE ENTERED THE NATIONAL PHASE - NAME INDEX UNDER THE NAME NANJINGJINSIRUI SCIENCE & TECHNOLOGY BIOLOGY CORP., APPLICATION NO. 2019415848, UNDER INID (71) CORRECT THE APPLICANT NAME TO NANJING GENSCRIPT BIOTECH CO., LTD.